Terms: = Kidney tumors AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025
9 results:
1. Overexpression of
Tran OT; Tadesse S; Chu C; Kidane D
Tumour Biol; 2020 May; 42(5):1010428320918404. PubMed ID: 32364878
[TBL] [Abstract] [Full Text] [Related]
2. Plectin-1 Targeted Dual-modality Nanoparticles for Pancreatic Cancer Imaging.
Chen X; Zhou H; Li X; Duan N; Hu S; Liu Y; Yue Y; Song L; Zhang Y; Li D; Wang Z
EBioMedicine; 2018 Apr; 30():129-137. PubMed ID: 29574092
[TBL] [Abstract] [Full Text] [Related]
3. [DNA repair XRCC1, XPD genes polymorphism as associated with the development of bladder cancer and renal cell carcinoma].
Akhmadishina LZ; Giliazova IR; Kutlyeva LR; Korytina GF; Kochetova OV; Urmantsev MF; Izmaĭlova SM; Izmaĭlov AA; Kunsbaeva GB; Zagidullin AA; Haliullin AA; Pavlov VN; Viktorova TV; Husnutdinova EK
Genetika; 2014 Apr; 50(4):481-90. PubMed ID: 25715450
[TBL] [Abstract] [Full Text] [Related]
4. Cadmium and cancer.
Hartwig A
Met Ions Life Sci; 2013; 11():491-507. PubMed ID: 23430782
[TBL] [Abstract] [Full Text] [Related]
5. xpa-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.
Aufderklamm S; Hennenlotter J; Todenhoefer T; Gakis G; Schilling D; Vogel U; Kuehs U; Dlugosch J; Knapp J; Merseburger A; Gerber V; Ordelheide A; Hevler J; Stenzl A; Schwentner C
World J Urol; 2012 Aug; 30(4):547-52. PubMed ID: 21969130
[TBL] [Abstract] [Full Text] [Related]
6. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.
Rafnar T; Vermeulen SH; Sulem P; Thorleifsson G; Aben KK; Witjes JA; Grotenhuis AJ; Verhaegh GW; Hulsbergen-van de Kaa CA; Besenbacher S; Gudbjartsson D; Stacey SN; Gudmundsson J; Johannsdottir H; Bjarnason H; Zanon C; Helgadottir H; Jonasson JG; Tryggvadottir L; Jonsson E; Geirsson G; Nikulasson S; Petursdottir V; Bishop DT; Chung-Sak S; Choudhury A; Elliott F; Barrett JH; Knowles MA; de Verdier PJ; Ryk C; Lindblom A; Rudnai P; Gurzau E; Koppova K; Vineis P; Polidoro S; Guarrera S; Sacerdote C; Panadero A; Sanz-Velez JI; Sanchez M; Valdivia G; Garcia-Prats MD; Hengstler JG; Selinski S; Gerullis H; Ovsiannikov D; Khezri A; Aminsharifi A; Malekzadeh M; van den Berg LH; Ophoff RA; Veldink JH; Zeegers MP; Kellen E; Fostinelli J; Andreoli D; Arici C; Porru S; Buntinx F; Ghaderi A; Golka K; Mayordomo JI; Matullo G; Kumar R; Steineck G; Kiltie AE; Kong A; Thorsteinsdottir U; Stefansson K; Kiemeney LA
Hum Mol Genet; 2011 Nov; 20(21):4268-81. PubMed ID: 21750109
[TBL] [Abstract] [Full Text] [Related]
7. Exposed proliferation antigen 210 (xpa-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications.
Kruck S; Hennenlotter J; Vogel U; Schilling D; Gakis G; Hevler J; Kuehs U; Stenzl A; Schwentner C
BJU Int; 2012 Feb; 109(4):634-8. PubMed ID: 21711439
[TBL] [Abstract] [Full Text] [Related]
8. xpa-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.
Gakis G; Hennenlotter J; Scharpf M; Hevler J; Schilling D; Kuehs U; Stenzl A; Schwentner C
World J Urol; 2011 Dec; 29(6):801-6. PubMed ID: 21113600
[TBL] [Abstract] [Full Text] [Related]
9. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma.
Lin J; Pu X; Wang W; Matin S; Tannir NM; Wood CG; Wu X
Carcinogenesis; 2008 Nov; 29(11):2112-9. PubMed ID: 18711149
[TBL] [Abstract] [Full Text] [Related]
